Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism

BACKGROUND: Apabetalone (RVX-208) is a bromodomain and extraterminal protein inhibitor (BETi) that in phase II trials reduced the relative risk (RR) of major adverse cardiac events (MACE) in patients with cardiovascular disease (CVD) by 44% and in diabetic CVD patients by 57% on top of statins. A ph...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Clin Epigenetics
Päätekijät: Tsujikawa, Laura M., Fu, Li, Das, Shovon, Halliday, Christopher, Rakai, Brooke D., Stotz, Stephanie C., Sarsons, Christopher D., Gilham, Dean, Daze, Emily, Wasiak, Sylwia, Studer, Deborah, Rinker, Kristina D., Sweeney, Michael, Johansson, Jan O., Wong, Norman C. W., Kulikowski, Ewelina
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2019
Aiheet:
Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6626370/
https://ncbi.nlm.nih.gov/pubmed/31300040
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13148-019-0696-z
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia